triazoles has been researched along with Hyperglycemia in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 3 (7.89) | 29.6817 |
| 2010's | 34 (89.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyazaki, S; Mori, Y; Taniguchi, Y; Utsunomiya, K; Yokoyama, J | 1 |
| Katznelson, L | 1 |
| Ando, K; Morimoto, A; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K | 1 |
| Anderson, MS; Engel, SS; Hanson, ME; Musliner, T; Steinberg, H | 1 |
| Farrokhi, F; Gianchandani, R; Jacobs, S; Lathkar-Pradhan, S; Newton, C; Pasquel, F; Peng, L; Reyes, D; Smiley, D; Umpierrez, GE; Wesorick, DH | 1 |
| Fujimoto, M; He, P; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Watanabe, K; Yamaga, M; Yokote, K | 1 |
| Gahler, RJ; Grover, GJ; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
| Hanaoka, H; Hashimoto, N; Ishikawa, K; Kanatsuka, A; Kobayashi, K; Kuribayashi, N; Onishi, S; Sakurai, K; Sato, Y; Takemoto, M; Terano, T; Uchida, D; Yokoh, H; Yokote, K | 1 |
| Ishida, H; Osonoi, T; Osonoi, Y; Saito, M; Tamasawa, A | 1 |
| Chi, J; Gu, W; Hong, J; Ning, G; Wang, B; Wang, W; Zhang, Y | 1 |
| Ahrén, B; Cirkel, DT; Feinglos, MN; Johnson, SL; Perry, C; Stewart, M; Yang, F | 1 |
| Inoue, T; Kyou, C; Morishita, K; Ogawa, T; Taguchi, Y; Umayahara, R; Yonemoto, T | 1 |
| Asai, S; Kato, H; Kondo, A; Nagai, Y; Ohta, A; Sada, Y; Sasaoka, T; Tanaka, Y | 1 |
| Aaboe, K; Akram, S; Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
| Ando, K; Nishimura, R; Sakamoto, M; Seo, C; Tsujino, D; Utsunomiya, K | 1 |
| Creekmore, A; Crowder, R; Doyle, A; Ellis, MJ; Erlichman, C; Gao, F; Guo, Z; Hoog, J; Lockhart, AC; Ma, CX; Naughton, M; Pluard, T; Sanchez, C | 1 |
| Butler, AE; Butler, PC; Cox, HI; Dry, S; Galasso, R; Gurlo, T; Matveyenko, AV; Moshtaghian, A | 1 |
| Fontés, G; Hagman, DK; Latour, MG; Poitout, V; Semache, M | 1 |
| Cefalu, WT | 1 |
| Davies, MJ; Engel, SS; Mavros, P; Radican, L; Rajagopalan, S; Yin, D; Zhang, Q | 1 |
| Kuritzky, L | 1 |
| Gerich, J | 1 |
| Bergman, BC; Cobelli, C; Hunerdosse, DM; Man, CD; Perreault, L | 1 |
| Opsteen, C; Qi, Y; Retnakaran, R; Vivero, E; Zinman, B | 1 |
| Matsuura, K; Mori, Y; Sezaki, K; Taniguchi, Y; Utsunomiya, K; Yokoyama, J | 1 |
| Chisholm, DJ; Douglas, A; Greenfield, JR; Gribble, FM; Holst, JJ; Piyaratna, N; Samocha-Bonet, D; Synnott, EL; Wong, O | 1 |
| Hurren, KM; Pinelli, NR | 1 |
| Ogawa, Y; Shimada, S; Tanaka, K | 1 |
| Aso, Y; Hara, K; Haruki, K; Inukai, T; Morita, K; Naruse, R; Ozeki, N; Shibazaki, M; Suetsugu, M; Takebayashi, K; Terasawa, T | 1 |
| Kishimoto, M; Noda, M | 1 |
| Davies, M; Speight, J | 1 |
| Allister, EM; Bhattacharjee, A; Wheeler, MB | 1 |
| Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P | 1 |
| Gahler, RJ; Grover, GJ; Juneja, P; Koetzner, L; Lyon, MR; Reimer, RA; Wood, S | 1 |
| Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K | 1 |
| Dailey, GE | 1 |
| Castro, L; Peluffo, G; Quijano, C; Radi, R; Valez, V | 1 |
| Fitzpatrick, JH; Gilboe, DD; Kintner, DB | 1 |
7 review(s) available for triazoles and Hyperglycemia
| Article | Year |
|---|---|
Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.
Topics: Biomarkers; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Lipids; Pyrazines; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2011 |
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Medication Adherence; Patient Satisfaction; Peptides; Pyrazines; Self Care; Sitagliptin Phosphate; Surveys and Questionnaires; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2012 |
Using prandial insulin to achieve glycemic control in type 2 diabetes.
Topics: Algorithms; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Postprandial Period; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
14 trial(s) available for triazoles and Hyperglycemia
| Article | Year |
|---|---|
Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inpatients; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-i
Topics: 1-Deoxynojirimycin; Aged; alpha-Glucosidases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastrointestinal Agents; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
Topics: Acarbose; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Drug Substitution; Drug Therapy, Combination; Female; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Isoindoles; Male; Middle Aged; Prospective Studies; Pyrazines; Serum Albumin; Sitagliptin Phosphate; Triazoles | 2014 |
Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp.
Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Follow-Up Studies; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2015 |
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2014 |
Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Japan; Kidney; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles | 2014 |
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2015 |
Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Isoindoles; Middle Aged; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Estradiol; Female; Fulvestrant; Heterocyclic Compounds, 3-Ring; Humans; Hyperglycemia; Hypoglycemic Agents; Maximum Tolerated Dose; Middle Aged; Nitriles; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose.
Topics: Aged; Blood Glucose; Body Mass Index; C-Peptide; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Hyperglycemia; Incretins; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Liver; Male; Middle Aged; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2010 |
Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pilot Projects; Placebos; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2010 |
Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
Topics: Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Japan; Male; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients.
Topics: Administration, Oral; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glutamine; Humans; Hyperglycemia; Insulin; Insulin Secretion; Male; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult | 2012 |
17 other study(ies) available for triazoles and Hyperglycemia
| Article | Year |
|---|---|
Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Pilot Projects; Postprandial Period; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.
Topics: Adrenocorticotropic Hormone; Central Nervous System Cysts; Delayed-Action Preparations; Dipeptidyl-Peptidase IV Inhibitors; Female; Growth Hormone-Releasing Hormone; Humans; Hyperglycemia; Hyperpigmentation; Middle Aged; Nelson Syndrome; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Somatostatin; Treatment Outcome; Triazoles | 2013 |
Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Inositol; Japan; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Sitagliptin improves postprandial hyperglycemia by inhibiting glucagon secretion in Werner syndrome with diabetes.
Topics: Diabetes Mellitus; Female; Glucagon; Humans; Hyperglycemia; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Werner Syndrome | 2013 |
Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Drug Combinations; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Sitagliptin Phosphate; Triazoles | 2014 |
Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
Topics: Administration, Oral; Aged; Algorithms; Biomarkers; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Japan; Male; Proinsulin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.
Topics: Amyloid; Animals; Animals, Genetically Modified; Arginine; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Clamp Technique; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Islet Amyloid Polypeptide; Islets of Langerhans; Metformin; Pyrazines; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate; Triazoles | 2009 |
Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.
Topics: Analysis of Variance; Animals; Blood Glucose; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Eating; Exenatide; Fat Emulsions, Intravenous; Gene Expression; Glucagon-Like Peptide 1; Glucose; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Lipids; Male; Peptides; Pyrazines; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Topics: Administration, Oral; Aged; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Electronic Health Records; Humans; Hyperglycemia; Hypoglycemic Agents; Individuality; Middle Aged; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; United States | 2010 |
Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Middle Aged; Pruritus; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Triazoles | 2012 |
Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Time Factors; Triazoles | 2012 |
A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Topics: 1-Deoxynojirimycin; Aged; Biomarkers; Blood Glucose; Case-Control Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Triazoles | 2011 |
MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucose; Glucose Intolerance; Homeostasis; Hyperglycemia; Hyperinsulinism; Incretins; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Obese; Phenylalanine; Triazoles | 2012 |
Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.
Topics: Alginates; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hyperglycemia; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Obesity; Polysaccharides, Bacterial; Pyrazines; Rats; Rats, Zucker; Satiation; Sitagliptin Phosphate; Triazoles | 2012 |
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin | 2012 |
Enhanced mitochondrial superoxide in hyperglycemic endothelial cells: direct measurements and formation of hydrogen peroxide and peroxynitrite.
Topics: Aconitate Hydratase; Animals; Catalase; Cattle; Cells, Cultured; Citric Acid Cycle; Endothelial Cells; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Glucose; Hydrogen Peroxide; Hyperglycemia; Immunohistochemistry; Membrane Potential, Mitochondrial; Microscopy, Fluorescence; Mitochondria; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Peroxynitrous Acid; Phenanthridines; Superoxides; Time Factors; Triazoles; Tyrosine | 2007 |
Hyperglycemic damage to mitochondrial membranes during cerebral ischemia: amelioration by platelet-activating factor antagonist BN 50739.
Topics: Animals; Azepines; Blood Pressure; Brain; Disease Models, Animal; Electroencephalography; Fatty Acids, Nonesterified; Fatty Acids, Unsaturated; Femoral Artery; Hyperglycemia; Intracellular Membranes; Ischemic Attack, Transient; Lipid Peroxidation; Male; Membrane Lipids; Mitochondria; Oxygen Consumption; Phospholipids; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Reference Values; Reperfusion; Thiobarbituric Acid Reactive Substances; Time Factors; Triazoles | 1997 |